| scholarly article | Q13442814 |
| P2093 | author name string | Debbie Hinnen | |
| Jodi Strong | |||
| P2860 | cites work | Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. | Q45049397 |
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. | Q47773960 | ||
| Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. | Q51278923 | ||
| Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. | Q51280414 | ||
| Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. | Q51284082 | ||
| Insulin analogues | Q81264332 | ||
| Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135 | Q88362274 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| Pancreatic safety of incretin-based drugs--FDA and EMA assessment | Q28308049 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy | Q34657801 | ||
| Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes | Q35372804 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study | Q36208628 | ||
| Impact of fixed-dose combination drugs on adherence to prescription medications | Q36572787 | ||
| Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study | Q36635502 | ||
| Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature | Q36872178 | ||
| The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. | Q37022665 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) | Q37106537 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people | Q37278100 | ||
| Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. | Q37345822 | ||
| Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials | Q37427294 | ||
| Adherence to therapies in patients with type 2 diabetes. | Q37468440 | ||
| Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes | Q37676824 | ||
| Optimizing outcomes for GLP-1 agonists. | Q37851264 | ||
| The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus. | Q37995650 | ||
| Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy | Q38597109 | ||
| Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. | Q38758454 | ||
| Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus | Q38989517 | ||
| Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes | Q39096167 | ||
| Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study | Q39156623 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). | Q44333619 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | insulin glargine | Q417317 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 145-154 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Diabetes spectrum : a publication of the American Diabetes Association | Q27722982 |
| P1476 | title | iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes | |
| P478 | volume | 31 |
| Q58612828 | Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study | cites work | P2860 |
Search more.